Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 -1.10%18 EBIT per Share is ₹15.35 as of Mar. 2026. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 813 Drug Manufacturers companies, Sudeep Pharma ranks better than 81.92% on this metric.
Sudeep Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was ₹5.65.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹15.35.
During the past 12 months, the average EBIT per Share Growth Rate of Sudeep Pharma was 16.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 36.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sudeep Pharma's EBIT per Share or its related term are showing as below:
BOM:544619'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 36 Med: 36 Max: 36
Current: 36
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Sudeep Pharma was 36.00% per year. The lowest was 36.00% per year. And the median was 36.00% per year.
BOM:544619's 3-Year EBIT Growth Rate is ranked better than 81.92% of 813
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs BOM:544619: 36.00
Sudeep Pharma's EBIT for the
three
months ended in Mar. 2026 was ₹630 Mil.
Sudeep Pharma (BOM:544619) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sudeep Pharma EBIT per Share Related Terms
Sudeep Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹15.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudeep Pharma (BOM:544619) has a EBIT per Share of ₹15.35 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sudeep Pharma and its competitors. According to the industry distribution chart, Sudeep Pharma ranks #147 out of 813 companies in the Drug Manufacturers industry, placing it in the top 18.1%.
Is Sudeep Pharma's EBIT per Share too high?
Sudeep Pharma's current EBIT per Share is ₹15.35. Based on the distribution chart, Sudeep Pharma ranks #147 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #147 out of 813 companies for EBIT per Share. This places Sudeep Pharma in the top 18% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current EBIT per Share is ₹15.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current EBIT per Share of ₹15.35. The current EBIT per Share is ₹15.35. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current EBIT per Share is ₹15.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score
Get the complete analysis for BOM:544619
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
